Fundus Camera Market Size And Trends

The global fundus camera market size is likely to be valued at US$ 654.1 million in 2025, reaching US$ 984.9 million by 2032 and exhibiting a CAGR of 6% during the forecast period 2025-2032. The expansion of geriatric population around the world and the heightening global burden of chronic illnesses such as diabetes are the two factors that are creating a massive demand for advanced ocular solutions.

Recent Market Trends

• AI-integrated fundus imaging systems are setting new benchmarks in diagnostic precision, outperforming human specialists in detecting retinal disorders, particularly in diabetic retinopathy and age-related macular degeneration screenings.
• Compact wide-field fundus cameras with ultra-high dynamic range (HDR) imaging are significantly enhancing diagnostic clarity, offering expansive field-of-view and improving peripheral lesion detection
• The non-mydriatic fundus camera segment leads the market share, as it is able to capture high-resolution retinal images without the need for pupil dilation.
• Major players in the fundus camera market are acquiring niche imaging technologies to enhance product portfolios, indicating a shift toward unified multimodal diagnostic platforms.
• Rising demand for handheld and portable fundus cameras in underserved and rural areas is accelerating, bolstered by the convergence of AI-readiness, battery-powered mobility, and the need for scalable eye screening models in emerging economies.

Fundus Camera in the News

• August 2025: Topcon Healthcare, Inc. acquired Intelligent Retinal Imaging Systems (IRIS), a U.S.-based company known for its cloud-based, AI-assisted diabetic retinopathy screening technology. This acquisition is a significant step in advancing Topcon's "Healthcare from the Eye" initiative, which aims to enhance connected care by integrating retinal disease screening into primary care settings. IRIS’s platform, which supports seamless electronic health record (EHR) integration and is compatible with a wide range of retinal cameras, enables primary care physicians and health systems to identify undiagnosed retinal diseases as part of routine preventive care.
• July 2025: Optomed USA launched the Optomed Lumo, a next-generation, portable, non-mydriatic handheld fundus camera designed to provide high-quality retinal imaging in a variety of healthcare settings, including primary care, community clinics, and remote locations. The device features a large 5-inch touchscreen with intuitive user guidance and programmable workflows to streamline imaging processes. It uses a patented High-Contrast Optical Design and a 12 MP high-sensitivity, low-noise CMOS sensor that delivers a wide 50-degree field of view for capturing detailed retinal images. The camera is FDA-cleared under the PJZ product code and designed to facilitate early detection of systemic diseases through retinal imaging, contributing to the emerging field of Oculomics.

Segment Analysis

The dominance of non-mydriatic fundus cameras, which hold nearly 49.4% of the fundus camera market share in the product category, is primarily due to their ability to capture high-resolution retinal images without pharmacologic dilation. This property makes them indispensable in diabetic retinopathy screening and routine ophthalmic exams. Hybrid fundus cameras offering dual mydriatic and non-mydriatic functionality are also gaining ground for their clinical flexibility, especially in multi-specialty settings.

In the modality segment, tabletop fundus cameras lead the pack with a share of over 53.8% on account of their superior image clarity and seamless integration with EHR systems, making them the default choice in hospitals and specialized eye care centers. Simultaneously, handheld fundus cameras are disrupting the established market structure by offering scalable, portable solutions for teleophthalmology, particularly in mobile health clinics and underserved regions.

Application-wise, diabetic retinopathy remains the top driver, with its position aided by the global rise in diabetes and the urgent adoption of early retinal diagnostics. According to the International Diabetes Federation (IDF), the number of diabetics in the world will jump from 537 million in 2021 to an estimated 783 million by 2045. On the end-user front, hospitals rule the roost, leveraging high-performance tabletop models for complex case management and large patient loads, while ophthalmology clinics and optometry practices are rapidly adopting fundus imaging systems to support preventive screening and long-term eye disease monitoring.

Regional Analysis

Among regions, North America is at the forefront, expected to hold an approximate 36.4% fundus camera market share in 2025. This dominance is driven by a highly robust, well-functioning healthcare infrastructure, widespread prevalence of diabetes and age-related macular degeneration, and an extensive deployment of advanced diagnostic imaging technologies across healthcare facilities in the U.S. and Canada.

In the U.S., portable fundus cameras are being increasingly integrated into emergency rooms, outpatient departments, and teleophthalmology programs. The expanding usage of AI-powered fundus imaging systems is enhancing diagnostic workflows and enabling earlier detection of retinal disorders. Europe is close on the heels of North America, propelled by strong digital health policies, efficient execution of diabetic retinopathy screening initiatives, and an active uptake of non-mydriatic and hybrid fundus cameras in primary care settings.

Countries such as Germany, France, and the UK are heading this shift, supported by favorable reimbursement models and public-private partnerships. On the other hand, Asia Pacific is set to be the fastest-growing market, fueled by the rising incidence of hypertension and diabetes, especially in India and China, along with government-led efforts to improve eye care in rural areas through mobile-compatible, AI-integrated ocular imaging solutions.

Industry Players

Established industry giants and budding regional players are competing intensely in the global fundus camera market. Carl Zeiss Meditec AG, Topcon Corporation, and NIDEK Co., Ltd. have been able to retain their stronghold in the market through the development and launch of advanced AI-integrated imaging systems, high-resolution tabletop fundus cameras, and seamless EHR integration, catering to hospitals and specialty ophthalmology clinics.

On the other hand, nascent manufacturers in Asia Pacific and Latin America are impressing the market with portable, non-mydriatic fundus cameras optimized for teleophthalmology and rural screening programs. At the same time, companies such as Optomed, Kowa, Centervue, and Optos are marking their territory by developing cost-effective, AI-ready devices tailored to regional screening needs and regulatory frameworks.